JPH02206763A - シアル酸を有する血中糖脂質複合体の選択的測定を行なうための分析方法 - Google Patents
シアル酸を有する血中糖脂質複合体の選択的測定を行なうための分析方法Info
- Publication number
- JPH02206763A JPH02206763A JP1131718A JP13171889A JPH02206763A JP H02206763 A JPH02206763 A JP H02206763A JP 1131718 A JP1131718 A JP 1131718A JP 13171889 A JP13171889 A JP 13171889A JP H02206763 A JPH02206763 A JP H02206763A
- Authority
- JP
- Japan
- Prior art keywords
- precipitate
- sialic acid
- solution
- methanol
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 132
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 129
- 210000004369 blood Anatomy 0.000 title claims abstract description 17
- 239000008280 blood Substances 0.000 title claims abstract description 17
- 229930186217 Glycolipid Natural products 0.000 title claims abstract description 15
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 238000004458 analytical method Methods 0.000 title claims description 16
- 238000005259 measurement Methods 0.000 title description 9
- 239000002131 composite material Substances 0.000 title 1
- 210000002966 serum Anatomy 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052751 metal Inorganic materials 0.000 claims abstract description 9
- 239000002184 metal Substances 0.000 claims abstract description 9
- 150000002632 lipids Chemical class 0.000 claims abstract description 8
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 7
- 230000007935 neutral effect Effects 0.000 claims abstract description 7
- 102000004895 Lipoproteins Human genes 0.000 claims abstract 2
- 108090001030 Lipoproteins Proteins 0.000 claims abstract 2
- 239000002244 precipitate Substances 0.000 claims description 183
- 239000000243 solution Substances 0.000 claims description 182
- 238000000605 extraction Methods 0.000 claims description 24
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000003791 organic solvent mixture Substances 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 2
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 2
- 229910001447 ferric ion Inorganic materials 0.000 claims description 2
- 229910001448 ferrous ion Inorganic materials 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 229910001453 nickel ion Inorganic materials 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 abstract description 3
- 238000001556 precipitation Methods 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000011877 solvent mixture Substances 0.000 abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 516
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 174
- 239000000203 mixture Substances 0.000 description 97
- 239000006228 supernatant Substances 0.000 description 83
- 208000014829 head and neck neoplasm Diseases 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 16
- 238000002156 mixing Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 description 12
- 208000029742 colonic neoplasm Diseases 0.000 description 12
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 206010033128 Ovarian cancer Diseases 0.000 description 11
- 239000012154 double-distilled water Substances 0.000 description 11
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 11
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 10
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 10
- 208000026037 malignant tumor of neck Diseases 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 9
- 239000001110 calcium chloride Substances 0.000 description 9
- 229910001628 calcium chloride Inorganic materials 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 239000011790 ferrous sulphate Substances 0.000 description 8
- 235000003891 ferrous sulphate Nutrition 0.000 description 8
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 description 8
- 229960002523 mercuric chloride Drugs 0.000 description 8
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 8
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- RLJMLMKIBZAXJO-UHFFFAOYSA-N lead nitrate Chemical compound [O-][N+](=O)O[Pb]O[N+]([O-])=O RLJMLMKIBZAXJO-UHFFFAOYSA-N 0.000 description 7
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 7
- 150000002339 glycosphingolipids Chemical class 0.000 description 6
- 229960001755 resorcinol Drugs 0.000 description 6
- 239000011592 zinc chloride Substances 0.000 description 6
- 235000005074 zinc chloride Nutrition 0.000 description 6
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 5
- 229960001763 zinc sulfate Drugs 0.000 description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000008606 intracellular interaction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100038736 Histone H3.3C Human genes 0.000 description 1
- 101001031505 Homo sapiens Histone H3.3C Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 231100000641 abortifacient agent Toxicity 0.000 description 1
- KBGAYAKRZNYFFG-BOHATCBPSA-N aceneuramic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO KBGAYAKRZNYFFG-BOHATCBPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001661 cadmium Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 125000001549 ceramide group Chemical group 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical group OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 235000015047 pilsener Nutrition 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- -1 silver ions Chemical class 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU2251-249/89 | 1989-01-23 | ||
HU24989 | 1989-01-23 | ||
HU2251-2190/89 | 1989-05-08 | ||
HU219089A HU208377B (en) | 1989-05-08 | 1989-05-08 | Analytic method for selective detecting glycolipid complexes carrying sial acid |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH02206763A true JPH02206763A (ja) | 1990-08-16 |
Family
ID=26317184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1131718A Pending JPH02206763A (ja) | 1989-01-23 | 1989-05-26 | シアル酸を有する血中糖脂質複合体の選択的測定を行なうための分析方法 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0515355A1 (da) |
JP (1) | JPH02206763A (da) |
KR (1) | KR910700457A (da) |
CN (1) | CN1044537A (da) |
AU (1) | AU3735689A (da) |
DK (1) | DK226590D0 (da) |
ES (1) | ES2012728A6 (da) |
FI (1) | FI913518A0 (da) |
NO (1) | NO903877D0 (da) |
WO (1) | WO1990008317A1 (da) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342567A (en) * | 1981-07-06 | 1982-08-03 | Sloan Kettering Institute For Cancer Research | Sialic acid determination method |
-
1989
- 1989-05-12 EP EP89905744A patent/EP0515355A1/en not_active Ceased
- 1989-05-12 AU AU37356/89A patent/AU3735689A/en not_active Abandoned
- 1989-05-12 WO PCT/HU1989/000021 patent/WO1990008317A1/en not_active Application Discontinuation
- 1989-05-12 KR KR1019900701970A patent/KR910700457A/ko not_active Application Discontinuation
- 1989-05-26 JP JP1131718A patent/JPH02206763A/ja active Pending
- 1989-06-06 ES ES8901972A patent/ES2012728A6/es not_active Expired - Fee Related
- 1989-06-20 CN CN89104207A patent/CN1044537A/zh active Pending
-
1990
- 1990-09-05 NO NO1990903877A patent/NO903877D0/no unknown
- 1990-09-20 DK DK226590A patent/DK226590D0/da not_active Application Discontinuation
-
1991
- 1991-07-23 FI FI913518A patent/FI913518A0/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK226590A (da) | 1990-09-20 |
AU3735689A (en) | 1990-08-13 |
WO1990008317A1 (en) | 1990-07-26 |
EP0515355A1 (en) | 1992-12-02 |
ES2012728A6 (es) | 1990-04-01 |
KR910700457A (ko) | 1991-03-15 |
CN1044537A (zh) | 1990-08-08 |
NO903877L (no) | 1990-09-05 |
DK226590D0 (da) | 1990-09-20 |
NO903877D0 (no) | 1990-09-05 |
FI913518A0 (fi) | 1991-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4226713A (en) | Diagnostic agents | |
Boyle et al. | Serum uric acid levels in normal pregnancy with observations on the renal excretion of urate in pregnancy | |
JPS6327659B2 (da) | ||
Hoppe et al. | Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography | |
Homburger | Evaluation of diagnostic tests for cancer. I. Methodology of evaluation and review of suggested diagnostic procedures | |
JPS62253399A (ja) | 脂質結合性シアル酸の測定法 | |
Malon et al. | Ionized magnesium in erythrocytes—the best magnesium parameter to observe hypo-or hypermagnesemia | |
US4414326A (en) | Diagnostic agents | |
CN113960232B (zh) | 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用 | |
ZAK et al. | Total and free cholesterol | |
US5045453A (en) | Method for determining sialic acid in plasma | |
KR900002747B1 (ko) | 암스크리닝 진단용의 개량된 밀론시약 | |
JPH02206763A (ja) | シアル酸を有する血中糖脂質複合体の選択的測定を行なうための分析方法 | |
US5296346A (en) | Method for determining lipid bound sialic acid in plasma | |
CN106841079A (zh) | 一种测定富含还原糖的蛋白样品中蛋白质含量的方法 | |
JPS5845562A (ja) | 体液中のβ―リポプロテインフラクシヨンの測定法 | |
Linker et al. | Problems in the analysis of urinary mucopolysaccharide excretion | |
CN115327129A (zh) | 一种血浆分子标志物犬尿氨酸在早期心力衰竭检测中的应用 | |
US5275952A (en) | Analytical method for the selective determination of sialic glycolipid complexes | |
EP0594873B1 (de) | Verfahren zur quantitativen Bestimmung von krankheitsspezifischen Antigenen und Vorrichtung zur Durchführung des Verfahrens | |
Adams et al. | Hemolysis in hematuria | |
CN107064505B (zh) | 一种基于核酸适体自催化作用的癌胚抗原检测试剂盒及其制备方法 | |
Fosbrooke et al. | Improved precision for the autoanalyser determination of serum cholesterol | |
JPH02242160A (ja) | 血液中の脂質結合シアル酸含量の測定方法 | |
US4012196A (en) | Colorimetric method for determining total lipids in human fluids |